Adenine base editor‐based correction of the cardiac pathogenic Lmna c. 1621C > T mutation in murine hearts
Journal of Cellular and Molecular Medicine · 2024
DOI: 10.1111/jcmm.18145 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Cellular and Molecular Medicine, 2024. Verfasst von Luzi Yang und 5 weiteren Autor:innen. Beteiligte Einrichtung: School of Basic Medical Sciences, Peking University Health Science Center, Beijing, China. Hauptthemen laut MEDLINE: Adenine, Gene Editing. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 17 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Key Research and Development Program of China, National Natural Science Foundation of China, Beijing Natural Science Foundation.
Abstract (Originalsprache)
Base editors are emerging as powerful tools to correct single‐nucleotide variants and treat genetic diseases. In particular, the adenine base editors (ABEs) exhibit robust and accurate adenine‐to‐guanidine editing capacity and have entered the clinical stage for cardiovascular therapy. Despite the tremendous progress using ABEs to treat heart diseases, a standard technical route toward successful ABE‐based therapy remains to be fully established. In this study, we harnessed adeno‐associated virus (AAV) and a mouse model carrying the cardiomyopathy‐causing Lmna c.1621C > T mutation to demonstrate key steps and concerns in designing a cardiac ABE experiment in vivo. We found DeepABE as a reliable deep‐learning‐based model to predict ABE editing outcomes in the heart. Screening of sgRNAs for a Cas9 mutant with relieved protospacer adjacent motif (PAM) allowed the reduction of bystander editing. The ABE editing efficiency can be significantly enhanced by modifying the TadA and Cas9 variants, which are core components of ABEs. The ABE systems can be delivered into the heart via either dual AAV or all‐in‐one AAV vectors. Together, this study showcased crucial technical considerations in designing an ABE system for the heart and pointed out major challenges in further improvement of this new technology for gene therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Basic Medical Sciences, Peking University Health Science Center, Beijing, China.
- Peking University Institute of Cardiovascular Sciences, Beijing, China.
- Department of Cardiology, Beijing Anzhen Hospital, Capital Medical University, Beijing, China.
- State Key Laboratory of Vascular Homeostasis and Remodeling, Peking University, Beijing, China.
- Beijing Key Laboratory of Cardiovascular Receptors Research, Beijing, China.
ORCID-Profile: Yuxuan Guo
Förderung
- National Key Research and Development Program of China
- National Natural Science Foundation of China
- Beijing Natural Science Foundation
- Beijing Nova Program
- Natural Science Foundation of Beijing Municipality
Zitieren
APA
Yang, L., Liu, Z., Sun, J., Chen, Z., Gao, F., & Guo, Y. (2024). Adenine base editor‐based correction of the cardiac pathogenic Lmna c. 1621C > T mutation in murine hearts. Journal of Cellular and Molecular Medicine. https://doi.org/10.1111/jcmm.18145
Vancouver
Yang L, Liu Z, Sun J, Chen Z, Gao F, Guo Y. Adenine base editor‐based correction of the cardiac pathogenic Lmna c. 1621C > T mutation in murine hearts. Journal of Cellular and Molecular Medicine. 2024. doi:10.1111/jcmm.18145
BibTeX
@article{Yang2024,
author = {Yang, Luzi and Liu, Zhanzhao and Sun, Jinhuan and Chen, Zhan and Gao, Fei and Guo, Yuxuan},
title = {Adenine base editor‐based correction of the cardiac pathogenic Lmna c. 1621C > T mutation in murine hearts},
journal = {Journal of Cellular and Molecular Medicine},
year = {2024},
doi = {10.1111/jcmm.18145}
}
EUVIMED